vs

Side-by-side financial comparison of Organogenesis Holdings Inc. (ORGO) and SILVERCORP METALS INC (SVM). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $223.8M, roughly 1.0× SILVERCORP METALS INC). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs -1.3%, a 20.7% gap on every dollar of revenue. Over the past eight quarters, SILVERCORP METALS INC's revenue compounded faster (87.6% CAGR vs 43.2%).

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

Silvercorp Metals Inc. (Silvercorp) is a Canadian-based, China-focused precious metals company engaged in the acquisition, exploration, and development of silver-containing properties.

ORGO vs SVM — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.0× larger
ORGO
$225.6M
$223.8M
SVM
Higher net margin
ORGO
ORGO
20.7% more per $
ORGO
19.4%
-1.3%
SVM
Faster 2-yr revenue CAGR
SVM
SVM
Annualised
SVM
87.6%
43.2%
ORGO

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ORGO
ORGO
SVM
SVM
Revenue
$225.6M
$223.8M
Net Profit
$43.7M
$-2.9M
Gross Margin
Operating Margin
28.1%
Net Margin
19.4%
-1.3%
Revenue YoY
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORGO
ORGO
SVM
SVM
Q4 25
$225.6M
$223.8M
Q3 25
$150.9M
Q2 25
$101.0M
$72.2M
Q1 25
$86.7M
Q4 24
$126.7M
$172.5M
Q3 24
$115.2M
$114.0M
Q2 24
$130.2M
$60.0M
Q1 24
$110.0M
Net Profit
ORGO
ORGO
SVM
SVM
Q4 25
$43.7M
$-2.9M
Q3 25
$21.6M
Q2 25
$-9.4M
$28.1M
Q1 25
$-18.8M
Q4 24
$7.7M
$42.1M
Q3 24
$12.3M
$28.0M
Q2 24
$-17.0M
$13.2M
Q1 24
$-2.1M
Gross Margin
ORGO
ORGO
SVM
SVM
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
ORGO
ORGO
SVM
SVM
Q4 25
28.1%
Q3 25
13.7%
Q2 25
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
30.5%
Q3 24
5.4%
30.7%
Q2 24
-10.7%
30.0%
Q1 24
-3.5%
Net Margin
ORGO
ORGO
SVM
SVM
Q4 25
19.4%
-1.3%
Q3 25
14.3%
Q2 25
-9.3%
39.0%
Q1 25
-21.7%
Q4 24
6.1%
24.4%
Q3 24
10.7%
24.5%
Q2 24
-13.1%
22.0%
Q1 24
-1.9%
EPS (diluted)
ORGO
ORGO
SVM
SVM
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORGO
ORGO
SVM
SVM
Cash + ST InvestmentsLiquidity on hand
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$300.1M
Total Assets
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORGO
ORGO
SVM
SVM
Q4 25
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$135.6M
Q3 24
$94.3M
Q2 24
$89.9M
Q1 24
$88.6M
Total Debt
ORGO
ORGO
SVM
SVM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
ORGO
ORGO
SVM
SVM
Q4 25
$300.1M
Q3 25
$255.1M
Q2 25
$233.2M
Q1 25
$242.9M
Q4 24
$262.9M
Q3 24
$278.5M
Q2 24
$263.5M
Q1 24
$278.0M
Total Assets
ORGO
ORGO
SVM
SVM
Q4 25
$598.7M
Q3 25
$509.8M
Q2 25
$461.1M
Q1 25
$467.4M
Q4 24
$497.9M
Q3 24
$446.3M
Q2 24
$443.2M
Q1 24
$458.5M
Debt / Equity
ORGO
ORGO
SVM
SVM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORGO
ORGO
SVM
SVM
Operating Cash FlowLast quarter
$39.4M
$107.9M
Free Cash FlowOCF − Capex
$34.8M
FCF MarginFCF / Revenue
15.4%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORGO
ORGO
SVM
SVM
Q4 25
$39.4M
$107.9M
Q3 25
$3.1M
Q2 25
$-32.9M
$40.0M
Q1 25
$-19.9M
Q4 24
$10.9M
$81.3M
Q3 24
$8.7M
$57.7M
Q2 24
$4.7M
$28.9M
Q1 24
$-10.2M
Free Cash Flow
ORGO
ORGO
SVM
SVM
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
$33.8M
Q2 24
$2.9M
$17.0M
Q1 24
$-12.4M
FCF Margin
ORGO
ORGO
SVM
SVM
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
29.6%
Q2 24
2.2%
28.3%
Q1 24
-11.3%
Capex Intensity
ORGO
ORGO
SVM
SVM
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
21.0%
Q2 24
1.4%
19.8%
Q1 24
2.0%
Cash Conversion
ORGO
ORGO
SVM
SVM
Q4 25
0.90×
Q3 25
0.14×
Q2 25
1.42×
Q1 25
Q4 24
1.43×
1.93×
Q3 24
0.71×
2.06×
Q2 24
2.19×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons